Say goodbye to plants: Synbio player Antheia earns new backers in quest to redesign flora-derived...

The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors view those cell engineering platforms. Now, a California company looking to do away with fragile flora supply chains in drug development has earned a new round of investment to chase its goal.

Read the article at Endpoints News.